Kezar Life Sciences, Inc.
KZR
$3.96
-$0.04-1.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -41.20% | -- | -29.20% | -31.58% | -22.39% |
| Gross Profit | 41.20% | -- | 29.20% | 2.96% | 22.39% |
| SG&A Expenses | -10.48% | -16.67% | -3.73% | -35.08% | -3.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.34% | -25.65% | -24.04% | -32.52% | -18.23% |
| Operating Income | 33.34% | 25.65% | 24.04% | 14.02% | 18.23% |
| Income Before Tax | 36.40% | 23.56% | 37.33% | 12.08% | 11.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 36.40% | 23.56% | 37.33% | 12.08% | 11.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 36.40% | 23.56% | 37.33% | 12.08% | 11.36% |
| EBIT | 33.34% | 25.65% | 24.04% | 14.02% | 18.23% |
| EBITDA | 33.66% | 25.90% | 24.20% | 14.10% | 18.45% |
| EPS Basic | 36.63% | 23.83% | -24.89% | 12.42% | 11.83% |
| Normalized Basic EPS | 31.95% | 23.82% | -54.62% | 12.42% | 17.89% |
| EPS Diluted | 36.63% | 23.83% | -24.89% | 12.42% | 11.83% |
| Normalized Diluted EPS | 31.95% | 23.82% | -54.62% | 12.42% | 17.89% |
| Average Basic Shares Outstanding | 0.36% | 0.35% | 0.36% | 0.39% | 0.53% |
| Average Diluted Shares Outstanding | 0.36% | 0.35% | 0.36% | 0.39% | 0.53% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |